Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Endpoints on Merck kGAa

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 21, 2022 1:01pm

119 Views

Post# 35115922

RE:RE:Endpoints on Merck kGAa

On October 06, 2022 and in a statement ahead of its capital markets day, the global conglomerate (MerckKGaA) said it will consider "larger-scale" acquisitions beginning in 2023.

[MerckKGaA and Pfizer are partnered sponsors in ONCY's Bracelet-1 Phase 2 metastatic breast cancer study involving "Pelareorep" + Merck KGaA/Pfizer's immune checkpoint inhibitor "Bavencio"]

Already, Merck KGaA has been investing to support its life science arm MilliporeSigma, most recently with the opening of a new facility in France. The move comes amid a five-year push by the company to increase sales from 19.7 billion euros in 2021 to 25 billion euros by 2025.

Aside from the investment in France, Merck KGaA's MilliporeSigma in June opened a $65 million high-potency active pharmaceutical ingredient site in Wisconsin. In May, the company unveiled a 440 million euro investment in Ireland.

https://www.fiercepharma.com/pharma/merck-kgaa-will-focus-big-3-business-sectors-consider-large-scale-acquisitions-2023-onwards